Rodriguez V, Richman S P, Benjamin R S, Burgess M A, Murphy W K, Valdivieso M, Banner R L, Gutterman J U, Bodey G P, Freireich E J
Cancer Res. 1977 Apr;37(4):980-3.
One hundred thirty-eight adults with advanced cancers were treated with Baker's Antifol. The complete response + partial response rate was only 10%. Best responses were obtained in 31 patients with lung adenocarcinoma (complete response + partial response, 13%), in 25 patients with colorectal carcinoma (partial response, 16%), and in 6 patients with renal cell carcinoma (partial response, 50%). Two partial responses occurred in 15 patients with squamous cancer. No significant responses were seen in 27 patients with other adenocarcinomas, 13 with sarcomas, 14 with melanomas, and 8 with miscellaneous tumors. The most frequent toxicities were dermatitis, stomatitis, gastrointestinal symptoms, and mild myelosuppression. The incidence of dermatitis was significantly decreased by shortening the schedule of Baker's Antifol administration from 5 to 3 days. Baker's Antifol has some degree of antitumor activity, and studies of combination of this agent with other effective chemotherapeutic agents are indicated.
138例晚期癌症成人患者接受了贝克抗叶酸剂治疗。完全缓解率+部分缓解率仅为10%。31例肺腺癌患者获得最佳缓解（完全缓解+部分缓解，13%），25例结直肠癌患者（部分缓解，16%），6例肾细胞癌患者（部分缓解，50%）。15例鳞状癌患者出现2例部分缓解。27例其他腺癌、13例肉瘤、14例黑色素瘤和8例其他肿瘤患者未见明显缓解。最常见的毒性反应为皮炎、口腔炎、胃肠道症状和轻度骨髓抑制。将贝克抗叶酸剂的给药方案从5天缩短至3天，皮炎的发生率显著降低。贝克抗叶酸剂具有一定程度的抗肿瘤活性，表明该药物与其他有效化疗药物联合使用的研究很有必要。
